Hunan Fangsheng Pharmaceutical Co., Ltd. Class A

Hunan Fangsheng Pharmaceutical Co., Ltd. Class A

SSSE:603998
10.54
CNY
+0.38
(+3.74%)
0.74EPS
13.94P/E
4.55BMarket Cap
Apr 23Next Earn

Total Valuation

CNY

As of September 30, 2026, Hunan Fangsheng Pharmaceutical Co., Ltd. Class A carries a market capitalization of 4.55B, placing it among publicly traded companies globally. Its enterprise value stands at 4.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.55B
Enterprise Value4.61B

Important Dates

Hunan Fangsheng Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for April 23, 2027.

Earnings Date4/23/2027

Share Statistics

As of September 30, 2026, Hunan Fangsheng Pharmaceutical Co., Ltd. Class A has 439.08M shares outstanding.

Shares Outstanding439.08M

Valuation Ratios

As of September 30, 2026, Hunan Fangsheng Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 13.94. The price-to-sales ratio is 2.43, and the price-to-book ratio stands at 2.56.

PE Ratio13.94
PS Ratio2.43
PB Ratio2.56
P/TBV Ratio3.64

Enterprise Valuation

As of September 30, 2026, Hunan Fangsheng Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 11.53 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 11.53 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 4.61B versus a market cap of 4.55B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.45
EV / EBITDA11.53
EV / EBIT11.53

Financial Position

As of September 30, 2026, Hunan Fangsheng Pharmaceutical Co., Ltd. Class A maintains a current ratio of 0.95, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.57, indicating elevated leverage, while an interest coverage ratio of 40.78 demonstrates strong ability to service its debt obligations.

Current Ratio0.95
Quick Ratio0.23
Debt / Equity11.57
Debt / EBITDA0.54
Interest Coverage40.78

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Hunan Fangsheng Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 19.12, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 14.98 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.69, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 15.39, useful for judging operating efficiency across full business cycles. The company generates approximately 1.00M in revenue per employee across its workforce of 1,868.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.28 indicates how many times Hunan Fangsheng Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)19.12
Return on Assets (ROA)10.69
Return on Invested Capital (ROIC)14.98
Return on Capital Employed (ROCE)15.39
Revenue Per Employee1.00M
Employee Count1,868.00
Inventory Turnover1.28

Taxes

CNY

Over the twelve months ended September 30, 2026, Hunan Fangsheng Pharmaceutical Co., Ltd. Class A recorded 67.49M in income tax expense. That works out to an effective tax rate of 17.09, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 394.90M, leaving 326.78M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax67.49M
Effective Tax Rate17.09

Stock Price Statistics

CNY

As of the close on November 17, 2026, Hunan Fangsheng Pharmaceutical Co., Ltd. Class A's stock has declined approximately 15.81% over the past 52 weeks. The 50-day moving average sits at 10.39, while the 200-day moving average is 10.56.

52-Week Price Change-15.81%
50-Day Moving Average10.39
200-Day Moving Average10.56

Income Statement

CNY

Over the twelve months ended September 30, 2026, Hunan Fangsheng Pharmaceutical Co., Ltd. Class A generated 1.88B in revenue and converted that into 326.78M in net income, yielding earnings per share of 0.74. EBITDA reached 399.57M, while operating income came in at 403.92M.

Revenue1.88B
Gross Profit1.40B
Operating Income403.92M
Pretax Income394.90M
Net Income326.78M
EBITDA399.57M
EBIT399.57M
Earnings Per Share (EPS)0.74

Balance Sheet

CNY

As of September 30, 2026, Hunan Fangsheng Pharmaceutical Co., Ltd. Class A holds 248.30M in cash and equivalents against 216.52M in total debt, resulting in a net debt position of -4.18M. Total book value stands at 1.78B, with working capital of -59.51M providing operational flexibility.

Cash & Cash Equivalents248.30M
Total Debt216.52M
Net Debt-4.18M
Equity (Book Value)1.78B
Book Value Per Share4.05
Working Capital-59.51M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-103.79M

Margins

Over the twelve months ended September 30, 2026, Hunan Fangsheng Pharmaceutical Co., Ltd. Class A posted a gross margin of 74.77, reflecting its pricing power and cost economics. The operating margin of 21.52 and net profit margin of 17.41 provide insight into operational efficiency.

Gross Margin74.77
Operating Margin21.52
Pretax Margin21.04
Profit Margin17.41
EBITDA Margin21.28

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Hunan Fangsheng Pharmaceutical Co., Ltd. Class A paid dividends of 0.52 per share. The dividend payout ratio of 69.46 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 11.27, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Hunan Fangsheng Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.52
Payout Ratio69.46
Shareholder Yield11.27

Stock Splits

Hunan Fangsheng Pharmaceutical Co., Ltd. Class A's most recent stock split took place on May 5, 2016 with a 1:3 split ratio.

Last Split Date5/5/2016
Split Ratio1:3

Scores

As of September 30, 2026, Hunan Fangsheng Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 4.09, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.09